NO20012916L - Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser - Google Patents

Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser

Info

Publication number
NO20012916L
NO20012916L NO20012916A NO20012916A NO20012916L NO 20012916 L NO20012916 L NO 20012916L NO 20012916 A NO20012916 A NO 20012916A NO 20012916 A NO20012916 A NO 20012916A NO 20012916 L NO20012916 L NO 20012916L
Authority
NO
Norway
Prior art keywords
compositions
methods
anorectal disorders
treating anorectal
treating
Prior art date
Application number
NO20012916A
Other languages
English (en)
Other versions
NO20012916D0 (no
Inventor
Thomas P Parks
Vivien Mak
Jung-Chung Lee
Charles Lee
Original Assignee
Cellegy Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012916(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellegy Pharma Inc filed Critical Cellegy Pharma Inc
Publication of NO20012916D0 publication Critical patent/NO20012916D0/no
Publication of NO20012916L publication Critical patent/NO20012916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20012916A 1998-12-14 2001-06-13 Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser NO20012916L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232598P 1998-12-14 1998-12-14
US13991699P 1999-06-17 1999-06-17
US15531899P 1999-09-21 1999-09-21
PCT/US1999/029459 WO2000035434A2 (en) 1998-12-14 1999-12-13 Compositions and methods for the treatment of anorectal disorders

Publications (2)

Publication Number Publication Date
NO20012916D0 NO20012916D0 (no) 2001-06-13
NO20012916L true NO20012916L (no) 2001-08-14

Family

ID=27381146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012916A NO20012916L (no) 1998-12-14 2001-06-13 Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser

Country Status (14)

Country Link
US (2) US6395736B1 (no)
EP (1) EP1143956A3 (no)
JP (1) JP2002542147A (no)
KR (1) KR20010093828A (no)
CN (2) CN1149983C (no)
AU (1) AU764921B2 (no)
BR (1) BR9916162A (no)
CA (1) CA2354543A1 (no)
CZ (1) CZ20012113A3 (no)
HU (1) HUP0104676A3 (no)
IL (1) IL143726A0 (no)
NO (1) NO20012916L (no)
PL (1) PL348817A1 (no)
WO (1) WO2000035434A2 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
GB9924636D0 (en) * 1999-10-18 1999-12-22 Norgine Bv Laxative preparation
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
WO2002009714A1 (en) * 2000-07-31 2002-02-07 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
IL159722A0 (en) * 2001-07-10 2004-06-20 Oligos Etc Inc Pharmaceutical compositions containing oligonucleotides
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
EP1434774A1 (en) 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
WO2003049593A2 (en) * 2001-12-06 2003-06-19 Duke University Prevention of flap necrosis in plastic surgery
AU2003213787A1 (en) * 2002-03-06 2003-09-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
US6863825B2 (en) 2003-01-29 2005-03-08 Union Oil Company Of California Process for removing arsenic from aqueous streams
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
US20060147504A1 (en) * 2004-12-30 2006-07-06 Bobby Corry Feminine anti-itch cloth
CA2595615C (en) * 2005-01-27 2014-05-20 C.B. Fleet Company Incorporated Feminine anti-itch gel
WO2006084913A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide
JP5429703B2 (ja) 2005-12-30 2014-02-26 モル リサーチ アプリケーションズ リミテッド 肛門括約筋を処置するための装置
AU2006335153B2 (en) * 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8066874B2 (en) 2006-12-28 2011-11-29 Molycorp Minerals, Llc Apparatus for treating a flow of an aqueous solution containing arsenic
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8252087B2 (en) 2007-10-31 2012-08-28 Molycorp Minerals, Llc Process and apparatus for treating a gas containing a contaminant
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
EP2445481B1 (en) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US8778969B2 (en) * 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
EP2512479B1 (en) * 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
CN102145004B (zh) * 2010-02-09 2012-03-21 鲁南制药集团股份有限公司 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
EP2790573A2 (en) 2011-12-16 2014-10-22 The Regents of The University of Michigan Digital manometry finger-mountable sensor device
CN103393690B (zh) * 2013-08-01 2016-05-11 南通大学附属医院 Katp通道开放剂在制备治疗术后疼痛药物中的应用
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
EP3113859A4 (en) 2014-03-07 2017-10-04 Secure Natural Resources LLC Cerium (iv) oxide with exceptional arsenic removal properties
RU2595799C1 (ru) * 2015-05-14 2016-08-27 Светлана Николаевна Суслина Композиция для лечения анальных трещин в форме крема
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
AU2019276832B2 (en) * 2018-06-01 2024-08-15 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
GB9119467D0 (en) * 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
ZA941027B (en) * 1993-02-16 1994-11-11 Smithkline Beecham Corp Chemical compounds
DE69429768T2 (de) * 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
US5948762A (en) * 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
PT1051972E (pt) * 1994-05-27 2007-12-07 Strakan Internat Ltd Uma Socie Composição dadora de óxido nítrico para tratamento de distúrbios anais
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
CA2270118A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6635678B1 (en) * 1996-12-23 2003-10-21 S.L.A. Pharma Ag Pharmaceutical composition for treating fecal incontinence
CN1298309A (zh) * 1998-02-27 2001-06-06 同步神经元有限责任公司 治疗肛门区疼痛的方法及其组合物
AU5995699A (en) * 1998-10-23 2000-05-15 Bunnage, Mark Edward Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
AU764921B2 (en) 2003-09-04
EP1143956A3 (en) 2001-12-12
HUP0104676A2 (en) 2002-06-29
PL348817A1 (en) 2002-06-17
CA2354543A1 (en) 2000-06-22
IL143726A0 (en) 2002-04-21
KR20010093828A (ko) 2001-10-29
NO20012916D0 (no) 2001-06-13
US20010012856A1 (en) 2001-08-09
BR9916162A (pt) 2001-09-04
AU2176300A (en) 2000-07-03
CN1526448A (zh) 2004-09-08
WO2000035434A2 (en) 2000-06-22
US6395736B1 (en) 2002-05-28
CN1149983C (zh) 2004-05-19
WO2000035434A3 (en) 2000-11-30
CZ20012113A3 (cs) 2001-11-14
HUP0104676A3 (en) 2005-12-28
CN1330539A (zh) 2002-01-09
EP1143956A2 (en) 2001-10-17
JP2002542147A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
NO20012916L (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DK1109453T3 (da) Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
NO991676L (no) FremgangsmÕter og sammensetninger for immunmodulering
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
NO20005017D0 (no) Metoder og viskøse sammensetninger for behandling av brønner
DE69926493D1 (de) Kühleinrichtung und kühlverfahren
NO20004896D0 (no) Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
DE69941874D1 (de) Optielektronisches bauelement und herstellungsverfahren
NO985385D0 (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren
FI965008A (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
DE69919340D1 (de) Überzugszusammensetzungen und verfahren
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DE69932573D1 (de) Wiedergabeverfahren und Wiedergabegerät
EP1064295A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS
NO20022057D0 (no) Fremgangsmåte og sammensetning for å behandle lungesykdommer
DE69918625D1 (de) Wiedergabegerät und Wiedergabeverfahren
PT1051172E (pt) Metodo para tratamento da dpco
NO20012099D0 (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application